Methods and products for treating subjects with autism spectrum disorders
Methods and products for treating a subject diagnosed with an autism spectrum disorder, an intellectual disability, an anxiety disorder, a mood disorder, a disorder of social interaction, irritability, aggression, self-injurious behavior, hyperactivity, inattention, or Fragile X syndrome or brain neuroinflammation by administering a tablet or liquid or a solid ODT or ODF or SMEDDS containing a ticagrelor or ticagrelor salt or combination with a second agent which may include a magnesium ion containing-compound, a zinc ion containing-compound, a lysine or lysine salt, an arginine or arginine salt, lecithin, or a combination thereof, wherein the ODT or ODF or SMEDDS releases >50% of the ticagrelor or a pharmaceutically acceptable salt thereof and >50% of the second agent within 15 minutes.
1. A method of treating a subject diagnosed with an autism spectrum disorder, an intellectual disability, epilepsy, an anxiety disorder, a mood disorder, a disorder of social interaction, irritability, aggression, self-injurious behavior, hyperactivity, inattention, Fragile X syndrome, or diagnosed with elevated TNFα, or diagnosed with elevated inflammatory cytokine marker of neuroinflammation comprising administering ticagrelor, an enantiomer thereof, or a pharmaceutically acceptable salt thereof to the subject or administering a combination of ticagrelor, an enantiomer thereof, or a pharmaceutically acceptable salt thereof with a second agent in a weight ratio of 1:0.1 to 1:50 to the subject, wherein the administering does not include administering antioxidants.
2. The method of claim 1 , comprising administering the ticagrelor or the combination orally or parenterally.
3. The method of claim 1 , comprising administering less than 60, 40, 30, or 20 mg/day of the ticagrelor, enantiomer or pharmaceutically acceptable salt thereof.
4. The method of claim 1 , comprising delivering the ticagrelor, enantiomer or pharmaceutically acceptable salt thereof such that a ticagrelor plasma level is sufficient to treat autism symptoms in a subject.
5. The method of claim 4 , wherein a ticagrelor plasma level of about 50-300 ng/mL is achieved in the subject.
6. The method of claim 4 , comprising delivering the ticagrelor, enantiomer or pharmaceutically acceptable salt thereof such that a ticagrelor plasma level sufficient to treat autism symptoms in a child or adult is maintained for at least 5 hours.
7. The method of claim 6 , wherein the maintained ticagrelor plasma level is about 50-300 ng/mL.
8. The method of claim 1 , further comprising maintaining a ticagrelor plasma level of about 50-300 ng/mL for at least 7 hours.
9. The method of claim 1 , further comprising maintaining a ticagrelor plasma level of about 80-200 ng/mL for at least 5 hours.
10. The method of claim 1 , further comprising maintaining a ticagrelor plasma level of about 80-200 ng/mL for at least 7 hours.
11. The method of claim 1 , comprising administering the ticagrelor or the combination orally.
12. The method of claim 11 , wherein the orally administering is via a solid orally disintegrating tablet (ODT) or a solid orally dissolving film (ODF) or a Self-microemulsifying drug delivery system (SMEDDS).
13. The method of claim 11 , wherein the orally administering is via a solid orally disintegrating tablet (ODT).
14. The method of claim 11 , wherein the orally administering is via a solid orally dissolving film (ODF).
15. The method of claim 11 , wherein the orally administering is via a Self-microemulsifying drug delivery system (SMEDDS).
16. The method of claim 1 , wherein the subject is diagnosed with an anxiety disorder.
17. The method of claim 1 , wherein the subject is diagnosed with irritability, aggression, self-injurious behavior, hyperactivity, or inattention.
18. The method of claim 1 , wherein the subject is diagnosed with Fragile X syndrome.
19. The method of claim 1 , wherein the subject is diagnosed with elevated TNFα.
20. The method of claim 1 , wherein the subject is diagnosed with an elevated inflammatory cytokine marker of neuroinflammation.
21. A method of treating a subject diagnosed with an autism spectrum disorder, an intellectual disability, epilepsy, an anxiety disorder, a mood disorder, a disorder of social interaction, irritability, aggression, self-injurious behavior, hyperactivity, inattention, Fragile X syndrome, or diagnosed with elevated TNFα, or diagnosed with elevated inflammatory cytokine marker of neuroinflammation comprising administering a combination of ticagrelor, an enantiomer thereof, or a pharmaceutically acceptable salt thereof with a second agent in a weight ratio of 1:0.1 to 1:50 to the subject, wherein the second agent is selected from the group consisting of a magnesium ion containing-compound, a zinc ion containing-compound, L-lysine or a salt thereof, L-arginine or a salt thereof, lecithin, or a combination thereof.
22. The method of claim 21 , comprising administering the ticagrelor or the combination orally.
23. The method of claim 21 , wherein the second agent is a magnesium ion containing-compound.
24. The method of claim 21 , wherein the second agent is a zinc ion containing-compound.
25. The method of claim 21 , wherein the second agent is L-lysine or a salt thereof.
26. The method of claim 21 , wherein the second agent is L-arginine or a salt thereof.
27. The method of claim 21 , wherein the second agent is lecithin.
28. A method of treating a subject diagnosed with an intellectual disability, irritability, aggression, self-injurious behavior, hyperactivity, inattention, Fragile X syndrome, or diagnosed with elevated TNFα, or diagnosed with elevated inflammatory cytokine marker of neuroinflammation comprising administering ticagrelor, an enantiomer thereof, or a pharmaceutically acceptable salt thereof to the subject or administering a combination of ticagrelor, an enantiomer thereof, or a pharmaceutically acceptable salt thereof with a second agent in a weight ratio of 1:0.1 to 1:50 to the subject, wherein the second agent is selected from the group consisting of a magnesium ion containing-compound, a zinc ion containing-compound, L-lysine or a salt thereof, L-arginine or a salt thereof, lecithin, or a combination thereof.